NCT03597516 is a Phase 3 clinical trial of RP-G28 in Lactose Intolerance, sponsored by Ritter Pharmaceuticals, Inc..

Who is sponsoring NCT03597516?

NCT03597516 is sponsored by Ritter Pharmaceuticals, Inc..

What drugs are being tested in NCT03597516?

Interventions in NCT03597516: RP-G28, Placebos.

What condition does NCT03597516 study?

NCT03597516 studies Lactose Intolerance.

Is NCT03597516 still recruiting?

NCT03597516 is currently completed. Last updated 8 July 2019.

Last reviewed 2019-07-08 · How we verify

NCT03597516

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

Completed Phase 3 Last updated 8 July 2019

What this trial tests

Phase 3 trial testing RP-G28 in Lactose Intolerance in 557 participants. Completed in 2 July 2019.

Timeline

26 June 2018

Primary endpoint
2 July 2019

2 July 2019

Quick facts

Lead sponsor	Ritter Pharmaceuticals, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	557
Start date	26 June 2018
Primary completion	2 July 2019
Estimated completion	2 July 2019
Sites	35 locations across United States

Drugs / interventions tested

RP-G28 — full drug profile →
Placebos — full drug profile →

Conditions studied

Lactose Intolerance — all drugs for Lactose Intolerance →

Sponsor

Ritter Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Lactose Intolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of RP-G28

Trials testing the same drug.

NCT03563846 — Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects · Phase 1 · completed

Other Ritter Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT03563846 — Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03597516 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ritter Pharmaceuticals, Inc.
Last refreshed: 8 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03597516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing